Literature DB >> 8280787

Screening for ferrochelatase mutations: molecular heterogeneity of erythropoietic protoporphyria.

X Wang1, M Poh-Fitzpatrick, S Taketani, T Chen, S Piomelli.   

Abstract

The DNA of 21 patients from 19 unrelated families with erythropoietic protoporphyria (EPP) were screened for the 6 ferrochelatase point mutations so far described. The mutation previously described by us (A >> T transversion at position -3 of the donor site of intron 10, causing exon 10 skipping) was detected in two additional unrelated EPP patients: in these patients, cDNA lacking exon 10 was also detected. The mutation described by Nakahashi et al. as responsible for exon 2 skipping (C >> T transition at position -23 of the acceptor site of intron 1), although also observed in some normal individuals, was invariably observed in all EPP patients tested and may thus play some role in the pathogenesis of EPP. Thus, it does not appear that this mutation is the primary mechanism underlying exon 2 skipping. None of the other four previously described mutations were detected. These data demonstrate the heterogeneity of the ferrochelatase locus and of the genetic defect in EPP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8280787     DOI: 10.1016/0925-4439(94)90077-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

2.  Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.

Authors:  J Bloomer; C Bruzzone; L Zhu; Y Scarlett; S Magness; D Brenner
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

3.  Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.

Authors:  Yongming Wang; Nathaniel B Langer; George C Shaw; Guang Yang; Liangtao Li; Jerry Kaplan; Barry H Paw; Joseph R Bloomer
Journal:  Exp Hematol       Date:  2011-05-11       Impact factor: 3.084

Review 4.  Theodore Woodward Award. Pathogenesis of biochemical abnormalities in protoporphyria.

Authors:  J R Bloomer; M B Poh-Fitzpatrick
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 5.  The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria.

Authors:  S Taketani; H Fujita
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

6.  Human ferrochelatase: a novel mutation in patients with erythropoietic protoporphyria and an isoform caused by alternative splicing.

Authors:  X Schneider-Yin; B W Schäfer; O Tönz; E I Minder
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

7.  Level of expression of the nonmutant Ferrochelatase allele is a determinant of biochemical phenotype in a mouse model of erythropoietic protoporphyria.

Authors:  Joseph Bloomer; Yongming Wang; Dongquan Chen
Journal:  Gene Regul Syst Bio       Date:  2008-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.